Qiagen

Verogen, Inc. is an independent forensic genomics company based in San Diego, California, that specializes in next-generation sequencing solutions tailored for law enforcement, criminal justice, and national security organizations. Founded in 2017, Verogen offers the MiSeq FGx forensic genomics solution, which enables the analysis of forensically relevant genetic markers in a single interrogation while automating cluster generation and eliminating sequencing errors. The company also provides ForenSeq universal analysis software, which aids in visualizing short tandem repeat (STR) and single nucleotide polymorphism (SNP) data, ensuring sample quality, and estimating ancestry, phenotype, and profile frequency statistically. By developing DNA-based biometric identification products, Verogen supports forensic laboratories and the global human identification community in resolving criminal cases and locating missing persons.

BLIRT S.A. is a biotechnology company based in Gdansk, Poland, specializing in the production of specialty enzymes and proteins for nucleic acid purification and sequencing. Founded in 2008, the company develops and commercializes both standardized and customized solutions tailored for the life sciences industry and diagnostic kit manufacturers. Its product offerings include a range of proteins and enzymes such as proteinases, RNase inhibitors, and polymerases, as well as molecular biology reagents like DNA and RNA extraction kits, PCR reagents, and electrophoresis products. Additionally, BLIRT provides contract services in biotechnology, microbiology, and chemical synthesis, focusing on the development of expression systems and methods for protein production in various hosts.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Actome is a biotechnology company that specializes in the development of advanced interactome technology aimed at enhancing life science research and personalized medicine. The firm employs a proprietary method that allows for the detection of single protein molecules and their interaction complexes. This technology translates the status of proteins into DNA barcodes through the use of DNA-labeled antibodies, facilitating detailed molecular biological research. Actome's innovations enable clients to analyze protein quantification, interactions, and post-translational modifications within biological samples, thereby contributing to advancements in pharmaceuticals and tailored therapeutic solutions.

Verogen, Inc. is an independent forensic genomics company based in San Diego, California, that specializes in next-generation sequencing solutions tailored for law enforcement, criminal justice, and national security organizations. Founded in 2017, Verogen offers the MiSeq FGx forensic genomics solution, which enables the analysis of forensically relevant genetic markers in a single interrogation while automating cluster generation and eliminating sequencing errors. The company also provides ForenSeq universal analysis software, which aids in visualizing short tandem repeat (STR) and single nucleotide polymorphism (SNP) data, ensuring sample quality, and estimating ancestry, phenotype, and profile frequency statistically. By developing DNA-based biometric identification products, Verogen supports forensic laboratories and the global human identification community in resolving criminal cases and locating missing persons.

NeuMoDx Molecular, Inc. is a molecular diagnostics company based in Ann Arbor, Michigan, that focuses on developing innovative solutions for molecular diagnostic testing in hospital and clinical reference laboratories. Established in 2012 and formerly known as Molecular Systems Corporation, NeuMoDx provides in-vitro testing tools designed to enhance the efficiency and cost-effectiveness of laboratory operations. The company's platform aims to increase the utilization of molecular diagnostics among medical providers, facilitating early disease identification and treatment. As of September 2020, NeuMoDx operates as a subsidiary of QIAGEN N.V.

N-of-One, Inc. is a molecular decision support company specializing in the interpretation of molecular test results for cancer care. The company provides clinicians with insights into disease-specific biological relevance, clinical evidence, and associated therapies. It interprets next-generation sequencing (NGS) data from solid and hematological tumors, circulating tumor cells, and DNA, as well as conducting copy number analysis and immunohistochemistry. N-of-One offers services such as PrecisionInsights, which delivers comprehensive clinical interpretation reports for gene NGS panels, and TRIALMATCH, a solution for matching patients with clinical trials based on their specific profiles. The company collaborates with commercial and hospital laboratories, as well as precision medicine programs, to enhance cancer treatment strategies. Founded in 2007 and based in Lexington, Massachusetts, N-of-One, Inc. operates as a subsidiary of QIAGEN N.V.

Parsagen Diagnostics is comprised of a team of passionate and driven leaders who have a proven ability to bring a product from conception through commercialization in multiple global markets. As they expand their presence in the US & abroad, they are looking for people who exhibit flexibility under pressure, who have a proclivity to seek & approach challenges with optimism and grit, and who can identify areas of need and contribute to their ultimate fulfillment.

ArcherDX, Inc. is a genomics company headquartered in Boulder, Colorado, specializing in the development and commercialization of advanced genetic analysis products. Established in 2013, the company focuses on next-generation sequencing technologies to enhance genetic mutation detection, particularly in oncology. ArcherDX offers a range of research-use-only products, including DNA-based VariantPlex, RNA-based FusionPlex, and ctDNA-based LiquidPlex assays. These products enable laboratories to conduct genomic analyses for therapy optimization and cancer monitoring. Additionally, ArcherDX provides customized assay design services for clinical and biopharmaceutical clients, allowing them to target specific biomarkers and develop new applications. The company aims to deliver actionable genomic information for the treatment of solid tumors, blood cancers, and sarcomas, catering to academic laboratories, biopharmaceutical firms, and contract research organizations. ArcherDX also seeks regulatory approval for various companion diagnostic assays to further support precision medicine initiatives.

STAT-Diagnostica is a company dedicated to the development of near-patient testing products aimed at enhancing healthcare delivery. It specializes in creating point-of-care diagnostic devices designed for rapid turnaround applications and critical care environments. The company's flagship product, DiagCORE, is a portable multi-analyte instrument that supports both molecular and immunoassay testing across various clinical settings. By integrating multiple testing techniques into a single device, STAT-Diagnostica enables healthcare professionals to streamline patient care and improve diagnostic efficiency.

OmicSoft Corporation specializes in developing bioinformatics software for the management, visualization, and analysis of biomarker data, with a focus on next-generation sequencing (NGS) and cancer genomics. Established in 2007 and based in Cary, North Carolina, the company offers an array of tools to assist researchers and scientists in analyzing their datasets and comparing them with extensive public genomic databases like The Cancer Genome Atlas. Key products include Array Suite, which provides comprehensive NGS bioinformatics tools; Genome Browser for genomic data visualization; and specialized databases such as CVMLand, ImmunoLand, OncoLand, and DiseaseLand, each designed for particular areas of genomic research. OmicSoft's solutions also include cloud-based analytics and customizable data analysis services, catering to the needs of pharmaceutical and biotech firms, universities, and research institutions globally. In January 2017, OmicSoft became a subsidiary of QIAGEN N.V.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

MO BIO Laboratories, Inc., founded in 1993 and based in Carlsbad, California, specializes in biotechnology research products, focusing on DNA and RNA isolation, protein extraction, and nucleic acid purification. The company develops and manufactures a range of products for life science research, including kits for soil, stool, and microbial nucleic acid purification. Additionally, MO BIO Laboratories provides sterility assurance services and certifications for various plastic and medical device suppliers, as well as for water and food quality. Its products are distributed both in the United States and internationally, with an online sales presence. As of 2015, MO BIO Laboratories operates as a subsidiary of Qiagen NV.

Protagen is a precision medicine company that specializes in drug development and patient management, particularly in the fields of autoimmune diseases and immuno-oncology. The company focuses on immuno-profiling and the discovery of novel autoantibody signatures, utilizing its SeroTag® technology to identify biomarkers that address challenges in the development of cancer immunotherapies and treatments for autoimmune conditions. Protagen is recognized for its expertise in patient stratification, having created disease-specific NavigAID panels that assess individual patients' autoimmune conditions and immune statuses. This tailored approach enables the development of more targeted therapies for various autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and Sjögren’s syndrome. Additionally, Protagen's biomarker discovery platform aids in the detection of autoantibodies in patients undergoing cancer immunotherapy, which helps predict treatment responses and supports informed therapeutic decisions.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

BIOBASE is a provider of expert-curated biological databases, software and services for the life sciences.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

CLC bio is a prominent provider of bioinformatics solutions, specializing in the analysis of genomic data derived from various high-throughput sequencing technologies. The company develops and sells enterprise software designed for both next-generation sequencing platforms and Sanger-based sequencing systems. By focusing on the needs of researchers and organizations in the life sciences, CLC bio enables users to efficiently interpret complex biological data, thus facilitating advancements in genomics and personalized medicine.

Ingenuity Systems is a developer of a software platform designed to support life science researchers by facilitating access to critical information. The platform enables enterprise customers to provide their researchers with resources through internal portals, search engines, and various software and workflow sources. This functionality allows researchers to effectively search, explore, visualize, and analyze biological and chemical data pertaining to genes, proteins, and small molecules, thereby enhancing their research capabilities and productivity in the life sciences field.

Drug Response Dx is a biotechnology company located in Hennigsdorf, Germany, founded in February 2012 by a team of experts including Dr. Zoltán Konthur, Dr. Jörg-M. Hollidt, Dr. Karl Skriner, and Dr. Joachim Rautter. The company specializes in developing biomarker tests specifically designed to evaluate treatment outcomes for rheumatoid arthritis (RA). Its tests focus on a protein that predicts the effectiveness of TNF-alpha inhibitors for individual patients prior to initiating medication. This approach facilitates timely treatment decisions and enhances the likelihood of successful therapeutic outcomes for patients suffering from RA. The company has established proof of concept using serum samples from RA patients, and its biomarker set is prevalidated, ensuring the reliability of its testing processes.

Intelligent Bio-Systems, established in 2005 by Drs. Steven J. Gordon and Jingyue Ju, specializes in developing advanced DNA sequencing systems. The company aims to enhance speed and reduce costs for generating sequence data, catering to both research and clinical applications, particularly in areas like cancer and HIV/AIDS studies. Their systems enable customers to achieve high-throughput sequencing at affordable prices while maintaining data quality.

AmniSure International is a medical diagnostics company specializing in the development of the AmniSure test, a highly accurate diagnostic tool for detecting ruptured fetal membranes (ROM) in pregnant women. Cleared by the FDA for marketing and approved in various international markets, the AmniSure test employs proprietary technology in a one-step, minimally invasive test strip that identifies small amounts of amniotic fluid in vaginal discharge. With results available within minutes at the point of care, the test boasts an accuracy rate of nearly 99%, significantly surpassing traditional diagnostic methods. The AmniSure assay has become a gold-standard solution in obstetric care, providing essential support in determining the health of both mother and fetus during pregnancy. It is also reimbursable under most U.S. state Medicaid plans, enhancing its accessibility for patients.

Xagenic Inc., based in Toronto, Canada, specializes in developing molecular diagnostics technology for rapid, decentralized testing. Their aim is to empower clinicians with on-demand, near-patient molecular testing capabilities, enabling timely treatment decisions and improving patient care while reducing healthcare costs. Xagenic's platform detects nucleic acids from clinical samples without the need for enzymes, delivering results in just 20 minutes. This allows for widespread diagnostic testing outside of traditional clinical laboratories, initially focusing on infectious disease tests.

Cellestis is manufactures and markets QuantiFERON products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses using whole blood samples.

Ipsogen is develops and markets diagnostic tests in the field of oncology worldwide. The company offers diagnostic kits and biomarkers. Its products are used in the diagnosis, prognosis, and monitoring of patients with leukemia.

ESE GmbH is a company that was acquired by Qiagen in 2010.

SABiosciences Corporation, established in 1998, is a privately held biotechnology company that focuses on advancing biological research in the post-genomic era. The company develops and commercializes a portfolio of real-time PCR-based assay panels that are designed to target specific diseases and biological pathways. By integrating hypothesis-driven and discovery-based research methodologies, SABiosciences aims to provide researchers with innovative tools that enhance the efficiency and effectiveness of their studies.

DxS (now a Qiagen company) is a personalized medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. Working in partnership with pharmaceutical companies, DxS will support the development and sales of targeted cancer therapies by providing companion diagnostic products and services. Since its founding in 2001, DxS has experienced considerable growth and firmly established itself as a leader in companion diagnostics, having recently secured deals with leading healthcare companies such as Amgen, Boehringer Ingelheim, and AstraZeneca. In addition, DxS has an exclusive agreement with Roche Diagnostics for the global distribution of its diagnostic products. DxS has a portfolio of cancer mutation products including both diagnostic and assays for research use. The TheraScreen® range of CE-marked (IVD) diagnostic* kits can identify genetic tumor mutations that affect how patients respond to cancer therapies, thus enabling doctors to provide the most beneficial treatment. DxS currently produce two diagnostic kits, TheraScreen K-RAS and TheraScreen EGFR29. The TheraScreen: K-RAS Mutation kit is a companion diagnostic for Vectibix® (Amgen) and Erbitux® (Merck KGaA) for the treatment of colorectal cancer. DxS was acquired by Qiagen (NASDQ : QGEN) and continues to operate from the heart of Manchester’s Technology Quarter in the UK.

Explera s.r.l. is a company focused on importing, manufacturing, and marketing products in the molecular biology sector, catering to research laboratories in Italy and internationally. The company provides a wide range of laboratory instruments and equipment, including thermal cyclers, ultra-compact thermal cycling products, and photo-documentation systems. Additionally, it offers various small equipment such as shakers, rotators, multi shakers, shakers-incubators, centrifuges, vortexes, thermostats, water baths, dry blocks, and magnetic stirrers, as well as biohazard and PCR cabinets. Through its diverse product portfolio, Explera supports the advancement of research and analytical activities in the life sciences field.

Corbett Life Science Pty., Ltd. is a manufacturer and distributor of advanced instrumentation systems specifically designed for the life sciences sector. Established in 1988 and headquartered in Sydney, Australia, the company offers a range of products including the Rotor-Gene, a real-time PCR cycler, and the CAS series of automated robots for PCR setup and precision liquid handling. Other notable products include the X-tractor Gene for nucleic acid extraction, the Palm-Cycler for thermal cycling, and the Gel-Scan 3000, an automated DNA sequencer. Corbett Life Science enhances laboratory efficiency by providing automation solutions for RNA/DNA extraction and real-time DNA analysis, serving clients globally across North America, South America, Europe, Asia, and beyond. The company has operating facilities in Sydney, Brisbane, Cambridgeshire, and San Francisco, and maintains a strategic partnership with Sigma-Aldrich. Corbett Life Science operates as a subsidiary of Qiagen NV and continues to be recognized for its innovative and user-friendly products that foster customer loyalty in the life sciences industry.

eGene, Inc. is a biotechnology company, engages in developing, manufacturing, and marketing analytical systems and reagents for the genotyping market. It uses capillary electrophoresis, microfluidics, reagents liquid handling, and automation technologies to create a DNA/RNA analysis system for biological materials and life sciences testing. The company offers HDA-GT12 genetic analyzer, which uses capillary electrophoresis-based technology for DNA/RNA separation. Its HDA-GT12 system is used to detect, quantify, identify, and characterize biological organisms, as well as to automate the routine and non-routine laboratory and industrial procedures.

Digene Corporation is develops, manufactures, and markets proprietary gene-based diagnostic tests for the screening, monitoring, and diagnosis of human diseases with a focus on women’s cancers and infectious diseases worldwide. The company primarily offers human papillomavirus (HPV) testing products, which are FDA-approved tests for the detection of HPV, are a reproducible, objective test for the primary cause of cervical cancer. Its primary product is The Digene HPV Test, a FDA-approved test for HPV, the primary cause of cervical cancer.

Genaco Biomedical Products, Inc. develops and markets medical genetic products and services in China. The company offers prenatal screening; neonatal screening; commercial kits for prenatal screening and diagnosis of common genetic diseases; cytogenetic equipment; molecular genetics equipment, such as gel boxes and power supplies; and general laboratory supplies. It distributes its products through distributors and medical genetic centers.

Gentra Systems, Inc. develops and markets nucleic acid purification reagents and instruments for clinical and clinical research laboratories. The company’s DNA and RNA purification products include Generation Kits, which provide DNA purification for small samples; Purescript kit that provides a non-toxic method for purifying RNA; Autopure ls instrument for processing samples, by purifying Puregene-quality DNA from blood samples; and Versagene RNA.

Shenzhen PG Biotech Co, Ltd., is a molecular biology company, engages in the development, manufacture, and marketing of research and clinic diagnosis reagents and instruments. Its integrated services include technical consultation, product introduction, and customer order upon request, as well as after-sale service. The company serves in the areas of scientific fields, including molecular biology, cell biology, genetics, microbiology, and management.

NeXtal Biotechnologies is a company based in Holland, Ohio, that specializes in the production of screens and plates for protein crystallization, a crucial aspect of structural biology studies and structure-based drug design. The company offers products tailored to meet the experimental needs of crystallization, including plates with grease-free independent screwable crystallization supports. As of January 8, 2020, NeXtal Biotechnologies operates as a subsidiary of CalibreScientific Inc.

Artus GmbH is a biotechnology company that specializes in the development, production, and sale of diagnostic kits utilizing advanced DNA analytical procedures. The company's primary focus is on polymerase chain reaction (PCR) and real-time PCR technologies, which are essential for identifying infectious agents. Artus's diagnostic kits are employed in various fields, including pharmacogenomics and veterinary diagnostics, facilitating more accurate and effective diagnoses for users.

Molecular Staging Inc., a life sciences tool company, specializes in developing technologies for the detection and measurement of proteins and nucleic acids. Its offerings include protein microarrays for proteomics research, whole-genome amplification tools to overcome limited DNA sample constraints, and multiplexed diagnostics for enhanced disease detection. These products cater to applications in genomics, pharmacogenomics, and diagnostics.

Xeragon is develops and markets products and services focusing on oligoribonucleotides (RNA). The company’s TOM-Amidite technology allows chemical synthesis of RNA and its siRNA technology helps in RNA synthesis and gene silencing. Xeragon’s products and services are used by RNA scientists in the fields of biopharmaceuticals, diagnostics, therapeutics, and structural studies.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

Ingenium Pharmaceuticals AG is discovers and develops molecules for the treatment of neuronal and autoimmune diseases.

Genoox, Ltd. is a company that develops a cloud-based platform dedicated to managing and analyzing genomic data. Founded in 2014 by Amir Trabelsi and Moshe Einhorn, the company is headquartered in Palo Alto, California. Genoox's platform harnesses artificial intelligence and machine-learning algorithms to translate complex genetic information into actionable clinical insights, thereby facilitating genetic diagnostics and personalized treatment options for patients. The platform connects clinicians, genetic counselors, and healthcare organizations, creating a collaborative network that enhances the sharing of genetic insights. With over 1,700 health organizations, hospitals, and medical facilities utilizing its services across 44 markets globally, Genoox aims to establish the largest real-world evidence network of genomic and clinical data, ultimately improving patient outcomes through more effective and efficient data handling.